GlassScriptPhysician profile
Paul Michael Palumbo
NPI 1184903361
$5,776.14
in general payments reported to CMS, 2019-2025
17 companies · $1,791 in 2025
The $1,791 reported for 2025 was more than what 96% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $78.98 · 2020: $28.66 · 2021: $97.00 · 2022: $754 · 2023: $611 · 2024: $2,416 · 2025: $1,791.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,942 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $1,875.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,942.07 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $1,875.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coopervision INC. | $2,519.07 | 2022-2025 | Misight Contact Lens, Myday Contact Lens |
| Lumenis Be INC | $877.03 | 2025 | Optilight |
| Abbvie INC. | $724.97 | 2022-2025 | |
| Alcon Vision LLC | $604.01 | 2019-2025 | Clareon, Clareon Panoptix Pro, Rocklatan |
| Glaukos Corporation | $259.30 | 2024-2025 | Idosetr, Idose |
| Johnson & Johnson Vision Care, INC. | $241.25 | 2020-2025 | |
| Bausch & Lomb Americas INC. | $204.58 | 2022-2025 | Infuse, Vyzulta, Miebo |
| Tarsus Pharmaceuticals, INC. | $75.02 | 2024-2025 | Xdemvy |
| Eyevance Pharmaceuticals LLC | $66.80 | 2022-2023 | Tobradex St, Flarex |
| Harrow Eye, LLC | $51.38 | 2025 | Vevye |
| Dompe US, INC. | $30.97 | 2025 | Oxervate |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $24.35 | 2019 | |
| Sun Pharmaceutical Industries INC. | $22.86 | 2023 | Cequa |
| Thea Pharma INC. | $20.75 | 2024 | Iyuzeh |
| Rxsight INC | $19.58 | 2021 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Oyster Point Pharma, INC. | $17.33 | 2024 | Ryzumvi, Tyrvaya |
| Allergan, INC. | $16.89 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Palumbo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.